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Genetic alterations analysis in 
prognostic stratified groups 
identified TP53 and ARID1A as poor 
clinical performance markers in 
intrahepatic cholangiocarcinoma
Michele Simbolo  1,2, Caterina Vicentini1,2, Andrea Ruzzenente3, Matteo Brunelli2, Simone 
Conci3, Matteo Fassan  1,6, Andrea Mafficini  1, Borislav Rusev1,2, Vincenzo Corbo1,2, Paola 
Capelli2, Emilio Bria7, Serena Pedron2, Giona Turri2, Rita T. Lawlor1,2, Giampaolo Tortora4, 
Claudio Bassi5, Alfredo Guglielmi3 & Aldo Scarpa  1,2
The incidence and mortality rates of intrahepatic cholangiocarcinoma have been rising worldwide. 
Few patients present an early-stage disease that is amenable to curative surgery and after resection, 
high recurrence rates persist. To identify new independent marker related to aggressive behaviour, 
two prognostic groups of patient were selected and divided according to prognostic performance. All 
patients alive at 36 months were included in good prognostic performers, while all patients died due 
to disease within 36 months in poor prognostic performers. Using high-coverage target sequencing 
we analysed principal genetic alterations in two groups and compared results to clinical data. In the 
33 cases included in poor prognosis group, TP53 was most mutated gene (p = 0.011) and exclusively 
present in these cases. Similarly, ARID1A was exclusive of this group (p = 0.024). TP53 and ARID1A are 
mutually exclusive in this study. Statistical analysis showed mutations in TP53 and ARID1A genes and 
amplification of MET gene as independent predictors of poor prognosis (TP53, p = 0.0031, ARID1A, 
p = 0.0007, MET, p = 0.0003 in Cox analysis). LOH in PTEN was also identified as marker of disease 
recurrence (p = 0.04) in univariate analysis. This work improves our understanding of aggressiveness 
related to this tumour type and has identified novel prognostic markers of clinical outcome.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy after hepato-
cellular carcinoma, and accounts for 10–20% of primary liver cancers1–3. The incidence and mortality rates of 
ICC have been rising worldwide in the past decade2,3. Moreover, only 10–20% of patients present with early-stage 
disease that is amenable to curative surgery4,5 and after resection, a high recurrence rate of 50–60% makes for a 
dismal five-year overall survival (OS) of only 30%5–8. As for patients with locally advanced or metastatic disease 
that constitute the bulk of newly diagnosed cases, even with the standard treatment of gemcitabine and cisplatin 
combination chemotherapy their median survival remains less than one year9. Molecular analyses suggested 
that the observed heterogeneity in prognosis and response to treatments could be attributed to the underlying 
differential alteration of the molecular mechanisms that drive crucial differences in cancer aggressiveness and 
treatment outcomes10,11.
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In this study, we composed two groups of intrahepatic cholangiocarcinomas patients with different prognostic 
performance. Using high-coverage targeted sequencing (HCTS), we investigated somatic mutations and copy 
number status of a large number of genes that have been identified as frequently altered by previous studies12–15 to 
uncover the molecular features characterizing the more aggressive subpopulation of this tumour type.
Results
Patient characteristics. A retrospective series (1990–2013) of 66 surgically-resected primary intrahepatic 
cholangiocarcinomas (ICC) was retrieved from the ARC-Net Biobank at Verona University Hospital. Clinico-
pathological characteristics of the sample cohort along with the molecular analyses conducted in this study are 
reported in Table 1. We selected patients according to the following criteria: i) minimum follow-up of 3 years; ii) 
availability of material for research; iii) no preoperative therapy received. All patient enrolled were subjected to 
surgical resection of primary tumour and presented negative liver fluke status. Hepatitis B or C virus (HBV/HCV) 
infection was present in 4/66 (6.1%) cases while liver fluke status was negative for all patients. Liver cirrhosis was 
present in 7/66 (10.6%) patients. Overall survival (OS) was available for all patients, while disease free survival 
(DFS) for 42 patients. The whole cohort of patients showed a median follow up of 40.7 months (range 2.0–152.7).
Patient grouping according to prognostic performance. For the present study, the sixty-six patients 
were divided into two groups based on clinical performance: patients alive at least 36 months (33 patients) were 
defined as good prognostic performers (GP group) and patients dead of disease within 36 months (33 patients) as 
poor prognostic performers (PP group). The PP group had a median follow up of 17.1 months (range 2.0–36.0) 
whereas the GP group had a median follow up of 61.3 (range 40.7–152.7). Clinicopathological characteristics of 
these two groups and of the whole cohort are shown in Table 1 and further detailed in Supplementary Table S1. 
Patient’s stratification is illustrated in Fig. 1. A higher rate of disease recurrence (p = 0.0006; Table 1) and a shorter 
time to recurrence among patients with negative resection margins (p < 0.0001; Fig. 1B) was observed in the PP 
group. Moreover, presence of liver cirrhosis was observed only in 7 patients of the PP group (p = 0.011). No dif-
ferences were found for the other variables.
Molecular features according to prognosis. DNA of tumour/normal matched samples from all cases 
was successfully amplified in multiplex PCR for 90 relevant genes chosen on the basis of published ICC sequenc-
ing studies, and an adequate library for HCTS was obtained. The mean read length was 109 bases and a mean 
coverage depth of 2537x was achieved, with 87.9% target bases covered more than 100x. A minimum coverage of 
20x was obtained in all cases. More specifically, HCTS yielded an average coverage of 1347x (40–3874x) in normal 
samples and 3728x (259–24725X) in tumour samples. Further detail of coverage depth per sample is reported in 
Supplementary Table S2.
The most frequently altered genes are shown in Fig. 2, distribution and frequencies of mutations in all 90 genes 
analysed are detailed in Table 2 and Supplementary Table S3. Copy number variations (CNVs) were assessed in 
18 genes and the results are reported in Table 3. FISH validation of representative cases affected by loss of hete-
rozygosity (LOH) and rearrangement of FGFR2 are illustrated in Supplementary Figures S1 and S2 respectively.
Mutations in one or more of the 90 analysed genes were observed in 56 cases (84.8%) of our series. In detail: 
one mutation was observed in 26 cases (39.4%), two or more in 30 cases (45.4%) while no alteration in 10 cases 
(15.2%). The most frequently mutated genes across the whole cohort were IDH1, KRAS (11 mutated cases each; 
16.7%), PBRM1 (10 cases; 15.2%) and BAP1 (9 cases; 13.6%).
CNVs for one or more of the 18 analysed genes were observed in 59 cases. In detail: one CNV was observed in 
6 cases (9.1%), more than one in 46 cases (69.7%) while no CNV was observed for 7 cases (10.6%). CNV analysis 
showed that loss of heterozygosis (LOH) or homozygous deletion (HD) of CDKN2A was most frequent event 
(24 cases; 36.4%), followed by LOH at the FHIT locus (19 cases; 28.8%) and copy gain of SRC (18 cases; 27.3%).
To further complement mutation and CNV analysis, all cases were screened through break-apart FISH probe 
to detect rearrangement of FGFR2, FGFR3 and ROS1 genes. A cut-off of 20% was used to define positive speci-
mens. Only one case showed rearrangement at the FGFR2 gene locus (Supplementary Figure S2). No other rear-
rangement was observed for FGFR3 and ROS1 at the defined cut-off of 20%.
Comparing the two prognostic groups (PP and GP), different mutational rates were observed: a mean of 2.3 
mutations per sample was obtained for the PP group whereas the average mutation rate was 1.5 for the GP group 
(Unpaired t-test p = 0.0007). Furthermore, one hyper-mutated sample was identified in the PP group, that is a 
sample characterized by a gross excess of point mutations relative to the same tumour type as analysed here and 
reported in current literature15–19. In particular, this case showed a missense mutation in POLE, a gene already 
linked to hyper-mutated genomic profiles in previous studies20,21. Two cases without mutations were observed in 
the PP group while in GP groups 8 cases showed no mutation. Differences between groups were observed in the 
number of CNVs as well, albeit not statistically significant. A mean of 3.3 CNVs per sample was observed in the 
PP group vs. a mean of 2.9 in the GP group.
As for altered genes prevalence (Fig. 2, Table 2), TP53 was the most frequently mutated gene of the PP group 
(8 cases; 24.2%; p = 0.011) and its mutation was exclusive to this group. ARID1A, IDH1, KRAS and PBRM1 dis-
played the second highest alteration frequency in the very same group (6 cases; 18.2%). ARID1A mutation was 
exclusive to this group as well (p = 0.024), and mutually exclusive with TP53 mutation. Of note, mutations of 
TGFBR2 (3 cases; 9.1%), BRAF and IGF2R (2 cases each; 9.1%) were present exclusively in the PP group, albeit at 
low rates. As for CNVs (Table 3), loss of one or both copies of CDKN2A and copy gain of MET (12 cases; 36.4%) 
were the most frequent events followed by copy gains in MYC (10 cases; 30.3%). LOH of TP53 was particularly 
enriched in this group (7 cases; 21.2%; p = 0.024) and associated to mutation at the same locus.
The 33 patients included in GP group had exclusive mutations in IDH2 (2cases; 3.0%), APC, ARAF, POLQ 
and RASA (1 case each; 1.5%), while it shared mutations in KRAS, IDH1, BAP1 and PIK3CA (5 cases each; 15.2%) 
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Clinico-pathological 
features Poor 33 Good 33 Total 66 p-value*
Sex 9F 24M 16F 17M 25F 41M 0.13
Age 67.8 ± 9.7 60.6 ± 13.6 65.0 ± 11.8 0.334^
Dimension (cm) 6.7 ± 4.4 6.1 ± 2.6 6.4 ± 3.6 0.478^
Median Follow-up (months) 17.1 61.3 40.7 <0.0001#
Range (2.0–40.0) (40.7–152.7) (2.0–152.7)
Median DFS (months) 7.4 61.7 14.2 <0.0001#
Range (2.8–26.4) (34.0–152.7) (6.3–152.7)
NA 10 14 24
Recurrence
1 22 11 33 0.006
0 1 8 9
NA 10 14 24
TNM Stage
1 2 10 12 0.084
2 12 8 20
3 7 5 12
4 12 10 22
Grade
1 3 4 7 0.226
2 19 24 43
3 11 5 16
R
2 1 0 1 0.278
1 5 2 7
0 27 31 58
Liver fluke status
Positive 0 0 0 —
Negative 33 33 66
HBV/HCV infection
Positive 4 0 4 0.11
Negative 29 33 62
Primary sclerosing cholangitis
Positive 0 0 0 —
Negative 33 33 66
Biliary stone disease
Positive 0 1 1 —
Negative 33 32 65
Liver cirrhosis
Positive 7 0 7 0.011
Negative 26 33 59
Multiple nodes
Present 16 10 26 0.207
Absent 17 23 40
Presence of BIN
Present 8 3 11 0.185
Absent 25 30 55
Vascular invasion
Present 28 20 48 0.051
Absent 5 13 18
Perineural invasion
Present 17 13 30 0.458
Absent 16 20 36
Table 1. Clinico-pathological features of 66 intrahepatic cholangiocarcinomas included in the study. Note: 
BIN, biliary intraepithelial neoplasia; DFS, disease free survival; NA, not available; R, resection margins. *Fisher 
exact test for multiple comparison was used as appropriated; ^Unpaired t-test; # Kaplan-Maier analysis.
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with the PP group. As for CNVs, the loss of CDKN2A was the most frequent event in the GP group (12 cases; 
36.4%), a feature shared with the PP group. The second most frequent event was LOH at FHIT locus (11 cases; 
33.3%). MYC copy gain (5 cases; 15.2%) was less frequently altered than in the PP group.
Survival analysis identified markers of poor outcome and disease recurrence. Pathological fea-
tures were matched to clinical data to identify poor prognostic markers. Grade, stage, sex and resection margins 
status were tested. Presence of positive resection margins (p < 0.0001) and advanced stage (p = 0.026) were iden-
tified as poor prognostic markers.
To investigate which of the previously identified molecular feature had the greatest impact on aggressive 
behaviour, we compared overall survival and progression free survival (PFS) curves in presence vs. absence of a 
specific alteration by univariate analysis.
Considering the whole cohort, we assessed the prognostic impact of principal differently distributed molec-
ular alterations between GP and PP groups: mutations in TP53; mutations in ARID1A; copy gains in MET; copy 
gains in MYC. LOH in TP53 was not considered because already included in the TP53 mutated cases. As illus-
trated in Fig. 3, alterations in TP53 (p = 0.0004), ARID1A (p = 0.009) and MET (p = 0.03) genes but not gain in 
MYC gene (p = 0.065) were predictors of poorer prognosis at univariate analysis.
Aggressive behaviour, measured as power of relapse, was tested using disease free survival and recurrence 
status in the 40 patients of our cohort that displayed negative resection margins. To perform this, we compared 
progression free survival (PFS) of these 40 cases grouping them on the basis of their clinicopathological and 
molecular features. At univariate analysis, we identified advanced tumour stage (p = 0.049) and LOH at PTEN 
gene locus (p = 0.04) as markers of earlier disease recurrence (Fig. 4).
Cox regression for multivariate survival analysis was used to test the independent prognostic value in intra-
hepatic cholangiocarcinomas of the previously identified molecular markers, selecting as candidates those char-
acterized by a p-value under 0.2 at univariate analysis. For clinical outcome, we tested the association of overall 
survival to mutation in TP53 and ARID1A, gains affecting MET and MYC loci, tumour stage, grade and resection 
margins status. Results are summarized in Table 4 and show that the resulting independent molecular predic-
tors of poor outcome were mutation of TP53 (p = 0.0031) and ARID1A (p = 0.0007), and copy gain of MET 
(p = 0.0003).
Figure 1. Grouping according to prognosis of 66 intrahepatic cholangiocarcinomas. (A) Overall survival 
significantly divided 66 intrahepatic cholangiocarcinoma in two prognostic performers group according 
to clinical outcome (p < 0.0001). (B) Prognostic grouping also divided intrahepatic cholangiocarcinomas 
characterized by negative resection margins in two different groups (p < 0.0001).
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Protein expression evaluation of principal markers. Immunohistochemical analysis was performed 
on all samples included in the study to evaluate protein expression level of candidate gene markers previous iden-
tified. We observed positive stain for p53 in all samples affected by missense mutation, while the case affected by 
a nonsense mutation showed no protein expression (Supplementary Figure S3A).
Similarly, arid1a immunolabelling was negative in presence of nonsense and frameshift mutations but not 
when samples were unaffected or affected by missense mutations (Supplementary Figure S3B).
Figure 2. Genetic alterations distinguished two prognostic performer groups. (A) Cases are grouped according 
to prognostic group (poor and good) previous defined by clinical outcome. The upper histogram shows the 
number of mutations (blue) and CNV (green) in recurrently altered genes for each sample. The central matrix 
shows 22 genes that were mutated in at least two cases of the whole cohort, 18 genes altered in copy number and 
3 genes shown rearrangement; alterations are annotated by different colour according to their impact on the 
gene product as illustrated in panel below. The number on the left reports the alteration frequency of each gene 
expressed as a percentage. (B) Fraction (%) of cases altered for each gene is represented by blue box or red box 
(when a statistical significant distribution was observed) according to prognostic group (poor prognosis on the 
left; good prognosis on the right).
www.nature.com/scientificreports/
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As for pten protein, we observed a generally low or negative immunolabelling irrespective of the presence of 
LOH, mutation, or no alteration at all.
Finally, we observed positive immunolabelling for c-met protein in those cases which had the MET locus 
affected by copy gain (Supplementary Figure S3C).
Discussion
The incidence and mortality rates of ICC have been rising worldwide in the past decade2 and only 10–20% of 
patients present with an early-stage disease amenable to curative surgery4,5. Molecular analyses have suggested 
that the observed heterogeneity in prognosis and response to treatments could be attributed to the underlying 
molecular mechanisms driving crucial differences in cancer aggressiveness and treatment outcomes11.
Gene
Poor Good Total Mutation type
p-value*33 [%] 33 [%] 66 [%] M N S D F
ALK 1 [3.0] 1 [1.5] 1 —
APC 1 [3.0] 1 [1.5] 1 —
ARAF 1 [3.0] 1 [1.5] 1 —
ARID1A 6 [18.2] 6 [9.1] 2 3 1 0.024
ARID1B 1 [3.0] 1 [1.5] 1 —
ATR 1 [3.0] 1 [3.0] 2 [3.0] 2 —
BAP1 4 [12.1] 5 [15.2] 9 [13.6] 5 3 1 —
BRAF 2 [6.0] 2 [3.0] 2 —
CHD4 1 [3.0] 2 [6.0] 3 [4.5] 1 1 1 —
ERBB3 1 [3.0] 1 [1.5] 1 —
ERBB4 1 [3.0] 1 [1.5] 1 —
FBXW7 1 [3.0] 1 [1.5] 1 —
FGFR3 1 [3.0] 1 [3.0] 2 [3.0] 2 —
HRAS 1 [3.0] 1 [1.5] 1 —
IDH1 6 [18.2] 5 [15.2] 11 [16.7] 11 —
IDH2 2 [6.0] 2 [3.0] 2 —
IGF2R 2 [6.0] 2 [3.0] 2 —
KDR 1 [3.0] 1 [1.5] 1 —
KIT 1 [3.0] 1 [1.5] 1 —
KMT2C 1 [3.0] 1 [3.0] 2 [3.0] 1 1 —
KMT2D 1 [3.0] 1 [1.5] 1 —
KRAS 6 [18.2] 5 [15.2] 11 [16.7] 11 —
MET 1 [3.0] 1 [1.5] 1 —
MLH1 1 [3.0] 1 [1.5] 1 —
MTOR 1 [3.0] 1 [1.5] 1 —
NF1 1 [3.0] 1 [1.5] 1 —
NRAS 2 [6.0] 3 [9.1] 5 [7.6] 5 —
PBRM1 6 [18.2] 4 [12.1] 10 [15.2] 5 4 1 —
PDGFRA 1 [3.0] 1 [1.5] 1 —
PIK3C2A 1 [3.0] 3 [9.1] 4 [6.1] 4 —
PIK3C2G 1 [3.0] 2 [6.0] 3 [4.5] 2 1 —
PIK3CA 2 [6.0] 5 [15.2] 7 [10.6] 6 1 —
PKHD1 2 [6.0] 2 [3.0] 2 —
PLCG1 1 [3.0] 1 [1.5] 1 —
POLE 1 [3.0] 2 [6.0] 3 [4.5] 3 —
POLQ 1 [3.0] 1 [1.5] 1 —
PTEN 2 [6.0] 1 [3.0] 3 [4.5] 1 2 —
PTPN11 1 [3.0] 1 [1.5] 1 —
RASA 1 [3.0] 1 [1.5] 1 —
STK11 1 [3.0] 1 [1.5] 1 —
TET1 2 [6.0] 2 [6.0] 4 [6.1] 4 —
TGFBR2 3 [9.1] 3 [4.5] 2 1 —
TP53 8 [24.2] 8 [12.1] 7 1 0.011
Table 2. Detailed mutational prevalence analysis of 66 intrahepatic cholangiocarcinomas. Related to Fig. 2. 
Note: M. missense; N. nonsense; S. splite site alteration; D. deletion; F. frameshift. *Fisher test for multiple 
comparison was used as appropriated.
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To date, many studies have been performed to uncover molecular features characterizing the different 
subtypes of cholangiocarcinoma and to infer mechanisms underlying its aggressive behaviour. Recently, two 
multi-omics studies were performed in unbiased large cohorts of cholangiocarcinomas identifying poor prog-
nostic hallmarks15,19. In particular, Nakamura et al. identified shorter survival in a group characterized by a higher 
mRNA expression of immune checkpoint genes15 while, Jusakul et al. identified the presence of liver fluke infec-
tion as a marker for poor prognosis19. In both studies a heterogeneous cholangiocarcinoma cohort (including 
gallbladder, extrahepatic and intrahepatic tumours) was used and survival analysis was performed on groups 
characterized by concomitant multiple alterations. Identification of these simultaneous alterations in diagnostic 
routine remains expensive and difficult to apply on archive material. Focusing on the intrahepatic subtype, to 
date several molecular studies were performed. In these, aside from mutations in TP5314,15,22,23, other different 
molecular alterations were identified as poor prognosis markers as IDH112, RNF4324, KRAS and ARID215. In all 
these studies, the experimental rationale was to start from a histopathologically defined cohort to identify new 
molecular and prognostic markers.
In this study, we followed a different experimental approach, using HCTS to analyse genetic alterations in 
two cohorts of ICC previously grouped according to their different prognostic performance. The idea of molec-
ularly characterizing different prognostic groups in order to investigate the potential existence of different driver 
alterations is innovative and promising, yet conceptually similar to treatment response trials or previous research 
works where clinicopathological variables were compared between 2 subgroups of patients distinct according to 
treatment response25 or prognosis26.
We selected and grouped 66 patients in two sub-cohorts according to the clinical performance showed within 
36 months: PP group (dead of disease at <36 months) and GP group (alive at >36 months). We confirmed 
a statistically significant difference between the two groups both for the prognostic performance in all cases 
(p < 0.0001) and for disease recurrence in negative resection margin cases (p < 0.0001).
Sequencing analysis evidenced different mutational rates between groups (p = 0.0033), with poor prognostic 
performers bearing a higher number of mutations, in keeping with a recent study in which a hyper-mutated pro-
file was associated to poorer prognosis15. Mutational analysis identified IDH1, BAP1, PBRM1 and KRAS as the 
most frequently altered genes, as in previous whole-exome and whole-genome sequencing studies12,13,15. Of note, 
coding sequence mutations of TP53 were found only in poor prognostic performers in our study, with a signifi-
cant discrepancy (p = 0.011) between groups. Similarly, we found mutations of ARID1A only in this prognostic 
group (p = 0.024). The association between mutations in TP53 and poor prognosis is not novel for intrahepatic 
cholangiocarcinomas15,22,23,27. In particular, Jayle et al. showed similar results in a large unbiased group of 224 
ICCs where TP53 resulted mutated in 24% of cases23. Differently, to date only low expression of ARID1A protein 
and mRNA were associated to poor prognosis in 57 intrahepatic cholangiocarcinomas analysed by Yang and 
colleagues. Although this corroborates our finding in suggesting a prognostic role of ARID1A in ICC, unfortu-
nately no mutational analysis was performed in that study28. Furthermore, a recent meta-analysis of Luchini et al. 
showed as mutation or low expression of ARID1A is a predictor of shorter disease specific survival and time to 
disease recurrence in cancer patients, but a direct correlation to ICC was not evident29.
Copy number variation analysis identified LOH in CDKN2A as the most frequent event, in keeping with pre-
vious studies15,30, with no difference in alteration rates between the two groups. Conversely, a higher proportion 
of cases affected by copy gain in MET and in MYC genes was observed in the PP group. The association between 
Gene
Poor Good Total
p-value*33 [%] 33 [%] 66 [%]
APC 2 [6.1] 1 [3.0] 3 [4.5] —
ARID1A 3 [9.1] 5 [15.2] 8 [12.1] —
CDKN2A 12 [36.4] 12 [36.4] 24 [36.4] —
CCND1 9 [27.3] 8 [24.2] 17 [25.8] —
EGFR 1 [3.0] 1 [3.0] 2 [3.0] —
EPHA7 4 [12.1] 6 [18.2] 10 [15.2] —
ERBB2 4 [12.1] 5 [15.2] 9 [13.6] —
FGFR3 9 [27.3] 5 [15.2] 14 [21.2] —
FHIT 8 [24.2] 11 [33.3] 19 [28.8] —
KRAS 8 [24.2] 9 [27.3] 17 [25.8] —
MET 11 [33.3] 5 [15.2] 16 [24.2] 0.15
MYC 10 [30.0] 5 [15.2] 15 [22.7] 0.24
PTEN 5 [15.2] 5 [15.2] 10 [15.2] —
RB1 2 [6.1] 2 [3.0] —
ROS 1 [3.0] 3 [9.1] 4 [6.1] —
SMAD4 4 [12.1] 4 [12.1] 8 [12.1] —
SRC 8 [24.2] 10 [30.3] 18 [27.3] —
TP53 7 [21.2] 7 [10.6] 0.024
Table 3. Detailed distribution of copy number variations detected in 66 intrahepatic cholangiocarcinomas. 
Related to Fig. 2. *Fisher test for multiple comparison was used as appropriated.
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c-MET and poor prognosis is not novel, as a previous study showed by immunohistochemistry that overex-
pression of this proto-oncogene is correlated to poorer outcome in patients affected by cholangiocarcinoma31. 
However, we herein show for the first time that patients affected by MET and MYC gene copy gain associate to a 
worse prognosis, suggesting that the enhanced expression of these loci may be due to a genetic lesion at least in a 
fraction of cases.
When we considered only cases with negative resection margins, only alterations affecting PTEN showed a 
prognostic impact on disease recurrence. Recently, heterozygous and homozygous deletion of PTEN locus in 
presence of KRAS activation was demonstrated to induce intrahepatic cholangiocarcinoma in cholangiocytes of a 
new mouse model32 showing an important role of PTEN in the development of this tumour type.
The main strength of the present work was the selection and focus on a well-defined cohort of resected ICC 
cases, grouped by prognostic performance. This however leads directly to the main limitation of the study, that 
suffers from a relatively small sample due to the difficulties in enrolling large numbers of resected patients with 
a minimum follow-up of 3 years, availability of material for research and no preoperative therapy. Despite that, 
our study shows a clear overlap with previous studies when dealing with already known associations (e.g. TP53 
mutation), while providing several interesting evidences about independent poor prognostic markers for intra-
hepatic cholangiocarcinomas. The preliminary stratification of patients according to prognosis also allowed the 
identification of some molecular aberrations whose absence in the GP group could explain an unusual degree or 
duration of the clinical benefit in selected cases of intrahepatic cholangiocarcinoma, as opposed to an otherwise 
relatively ineffective treatment in the rest of patients. The present work therefore confirms previous knowledge on 
the molecular landscape of ICC and suggests potential hallmarks of aggressiveness in this tumours that demand 
further validation but may be easily translated to the clinic for anticipating prognosis and response to therapy.
Figure 3. Univariate analysis identified poor prognostic markers in whole cohort. (A) Overall survival is 
significantly affected by mutations in ARID1A gene (p = 0.009); (B) TP53 gene (p = 0.0004) mutations and (C) 
copy gain in MET gene (p = 0.03).
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Materials and Methods
Patients and samples enrolled in the study. Tissue specimens and data from surgically-resected pri-
mary intrahepatic cholangiocarcinoma patients were retrieved from the ARC-Net Biobank at Verona University 
Hospital. Three criteria were considered to enrol patients in this study: i) minimum follow-up of 3 years; ii) 
availability of material for research; iii) no preoperative therapy received. According to the stated criteria, a ret-
rospective series (1990–2013) of 66 surgically-resected primary intrahepatic cholangiocarcinomas (ICC) was 
retrieved from the FFPE archives of the biobank under the local ethics committee approval (“Comitato etico per 
la sperimentazione clinica delle province di Verona e Rovigo” n. prog. 1959). All cases were reclassified by two 
pathologists (MF and AS) according to WHO 201033 and staged according to AJCC/UICC 7th edition34. In all 
cases, sufficient material for molecular analysis and construction of 1-mm cores tissue microarrays (TMAs) was 
available. Three tissue cores per case were included in the TMAs. Eighteen non-neoplastic samples (8 normal 
biliary duct and 10 chronic cholecystitis) were included in the TMAs as controls.
DNA extraction and qualification. DNA from tumour and matched non-neoplastic liver was extracted 
from formalin-fixed paraffin embedded (FFPE) tissue specimens. In particular, tumour DNA was prepared after 
enriching neoplastic cellularity to at least 70% by manual microdissection of 10 consecutive 4-μm sections: cases 
were revised by a pathologist that chose tissue areas according to two main features: i) absence of necrosis and ii) 
tissue histology had to be representative of the whole tumour. DNA was purified using the QIAamp DNA FFPE 
Tissue Kit (Qiagen), and qualified as reported elsewhere35,36.
Mutational analysis by next-generation targeted sequencing. Matched tumour/normal DNA from 
all cases was subjected to targeted next-generation sequencing (NGS). Two multigene panels were used to inves-
tigate mutational status of 90 genes: the 50-gene Ion AmpliSeq Cancer Hotspot panel v2 (Thermo Fisher) and 
one AmpliSeq custom panel (ICC custom panel 1) targeting 40 genes not included in the commercial panel. 
The first explores selected regions of 50 cancer-genes: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, 
CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, 
HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR/VEGFR2, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, 
NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL. 
Details on target regions of the commercial panel are at http://www.thermofisher.com. The custom panels targets 
40 genes selected on the basis of published WGA, exome and targeted sequencing studies: ACVR2A, ARAF, 
ARID1A, ARID1B, ARID2, ATR, BAP1, CHD4, DNMT3A, ELF3, EP300, EPHA2, EPHA6, EPHA7, GSK3A, 
Figure 4. Univariate analysis identified markers of disease recurrence in negative resection margins cases. (A) 
Disease recurrence is significantly affected by advanced stages and (B) LOH of PTEN gene.
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HERC2, KMT2A, KMT2C, KMT2D, MDC1, MSH6, MTOR, NF1, PBRM1, PIK3C2A, PIK3C2G, PKHD1, PLCG1, 
POLE, POLQ, PRKDC, RASA, RELN, RNF43, ROBO2, ROS, SF3B1, TET1, TET2, TGFBR212–15,24. Details on tar-
get regions of the commercial panel are at http://www.thermofisher.com while detail of region covered by ICC 
custom panel 1 are reported in Supplementary Table S4. Twenty ng of DNA were used for each multiplex PCR 
amplification. The quality of the obtained libraries was evaluated by Agilent 2100 Bioanalyzer on-chip electropho-
resis (Agilent Technologies). Emulsion PCR for clonal amplification of the libraries was performed with the Ion 
OneTouch™ OT2 System (Thermo Fisher). Sequencing was run on the Ion Proton (PI, Thermo Fisher) loaded 
with Ion PI Chip v2. Data analysis, including alignment to the hg19 human reference genome and variant calling, 
was done on the Torrent Suite Software v.5.0 (Thermo Fisher) utilizing the standard setup for somatic variants 
detection with minor modifications to further improve sensitivity (i.e. minimum variant frequency for indels 
was set to 0.05 instead of 0.15; complex variant detection was enabled). Called variants were annotated using 
a custom pipeline based on vcflib (https://github.com/ekg/vcflib), SnpSift37, the Variant Effect Predictor (VEP) 
software38 and NCBI RefSeq database. Confident somatic mutations were obtained from annotated variants by: 
i) filtering-out germline mutations identified in matched normal sample sequenced; ii) filtering-in mutations 
with at least 20 variant-containing reads and with variant frequency >10%; iii) ruling out sequencing artefacts 
by visual verification of normal and tumour samples alignments using the Integrative Genomics Viewer (IGV) 
v2.339. Alignments were visually verified with IGV also to confirm the presence of identified mutations.
Copy number variations of cholangiocarcinomas by next-generation sequencing. A second cus-
tom panel was specifically developed to investigate CNV status of 18 genes: APC, ARID1A, CDKN2A, CCND1, 
EGFR, EPHA7, ERBB2, FGFR3, FHIT, KRAS, MYC, MET, PTEN, RB1, ROS, SMAD4, SRC and TP53 (ICC custom 
panel 2, Supplementary Table S4). CNV analysis was performed on IonReporter Software v.5.0 (Thermo Fisher) 
utilizing the single-sample CNV workflow. According to this workflow, a baseline was created using the align-
ment files of 10 DNA samples from FFPE tissue of male healthy donors. Alignment files of tumour samples were 
then compared to the CNV baseline to determine CNV status. CNV calls were deemed confident according to 
the following criteria: i) a CNV confidence number major than 20; ii) a tiles number major than 10. For genes 
showing CNV calls with sub-optimal values, an orthogonal cross-validation using FISH or qPCR was performed. 
In this case, only CNV calls with concordant results of NGS and validation were reported. A statistical report of 
cross-validation rates is illustrated in Supplementary Table S5.
CNV validation by Quantitative PCR. Q-PCR analysis of copy numbers was applied to all samples for 
selected loci. All target and reference assays were purchased from Applied Biosystems. RNaseP was used as 
endogenous control for normalization of analysed loci. The following assays were used: CCND1 (Hs03772544), 
Covariate Odds-ratio 95% CI p-value*
TP53 wild type 1 — —
TP53 mutated 5.458 1.7729 to 16.8033 0.0031
ARID1A wild type 1 — —
ARID1A mutated 6.9059 2.2710 to 21.0008 0.0007
MET wild type 1 — —
MET gain 4.6312 2.0210 to 10.6126 0.0003
MYC wild type 1 — —
MYC gain 1.6521 0.7391 to 3.6929 0.2212
Stage I 1 — —
Stage II 1.8791 0.4878 to 7.2383 0.3592
Stage III 7.4306 2.0001 to 26.6060 0.0027
Stage IV 2.7035 0.7327 to 9.9752 0.1354
Grade 1 1 — —
Grade 2 0.7426 0.1978 to 2.7885 0.6593
Grade 3 2.09 0.5534 to 7.8932 0.2769
Negative resection 





Table 4. Multivariate survival analysis of 66 intrahepatic cholangiocarcinomas; median overall survival was 
40.7 months and 41 subjects died of disease. *Cox proportional-hazards regression analysis. Selection of the best 
model was performed using the “forward” algorithm.
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FHIT (Hs03491211), MET (Hs04951661), SRC (Hs07169853) and RNaseP (part number 4403326). The experi-
mental procedure recommended by the manufacturer (Applied Biosystems) was followed. Twenty ng of genomic 
DNA were used in the q-PCR reaction and a negative control was analysed in parallel. All q-PCR reactions were 
run in quadruplicate in a 7900HT qRT-PCR machine (Applied Biosystems) using standard cycling conditions of 
10 min at 95 °C, followed by 40 cycles of [95 °C for 15 sec and at 60 °C for 1 min]. Pooled normal FFPE DNA was 
used as calibrator.
Fluorescent in situ hybridization (FISH). A FISH analysis was developed according manufacturer 
instruction for following genes to validate Copy Number Variation obtained by NGS analysis: CDKN2A, EGFR, 
ERBB2, FGFR3, MYC, MET, PTEN, ROS and TP53 (all probes Vysis/Abbott Molecular). Analysis was performed 
for all samples; data interpretation was performed as reported elsewhere40–43 and cross-validation rates are illus-
trated in Supplementary Table S5. FISH analysis was also used to identify rearrangement for followed genes: 
FGFR2 (ZytoVision Molecular Diagnostics), FGFR3 (CGI) and ROS1 (Vysis/Abbott Molecular). FISH analy-
sis was firstly performed on TMA for all cases. Cases showing a positive signal in at least 15% of nuclei were 
re-analysed by FISH on whole sections. A presence of rearrangement in at least 20% of cells was considered pos-
itive. Representative cases of PTEN and TP53 monosomy and CDKN2A homozygous deletion are illustrated in 
Supplementary Figure S1, while the only case with confirmed FGFR2 rearrangement is shown in Supplementary 
Figure S2.
Immunohistochemistry. The immunohistochemical staining was performed with a Leica Microsystems 
Bond-Max Autostainer System according to manufacturer protocols. Arid1a (clone EPR13501–73, Abcam, 
dilution 1:1000), met (clone 4F8.2, Sigma Aldrich, dilution 1:250), pten (clone 138G6, Cell Signaling, dilution 
1:100) and p53 (clone DO-1, Immunotech, dilution 1:50) were applied to consecutive 4-μm FFPE TMA sections. 
Appropriate positive and negative controls were run concurrently. Representative cases altered in p53, arid1a and 
met are shown in Supplementary Figure S3.
Statistical analysis. One-way ANOVA, Kruskal-Wallis test, Fisher’s test with Monte Carlo simulation, and 
Fisher’s exact test corrected for multiple comparisons were used as appropriate. For comparison of Kaplan-Meier 
survival curves, Mantel-Cox log-rank test was used; for multivariate survival analysis, stepwise Cox proportional 
hazards regression was used; selection of the best model was performed using the “backward elimination” algo-
rithm. For all the analyses, a p-value below 0.05 was considered significant. All analyses were performed using 
Medcalc for Windows version 15.6 (MedCalc Software, Ostend, Belgium) and R v. 3.2.1; multivariate Cox regres-
sion was done with R using survival library v.2.38-2.
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